FDA Peptide Update: What Changed Since the July Advisory Committee Vote
In July, we published a preview of the FDA’s July 2026 Pharmacy Compounding Advisory Committee meeting, written before anyone knew how it would go. Four months later, there is a lot more to report. The committee voted, the FDA’s own scientists disagreed with it, and on October 28 the U.S. Department of Health and Human Services (HHS) issued a new policy that changes how certain peptides can be handled by compounding pharmacies, at least for now.
This post explains the new FDA peptide enforcement discretion policy, walks through what led to it in order, and covers what it does and does not mean for the research peptide market.
The short answer
- July 23–24: The FDA’s Pharmacy Compounding Advisory Committee (PCAC) narrowly voted to recommend six of the seven peptides it reviewed: BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax. It voted against the seventh, emideltide (also known as DSIP).
- October 28: HHS announced limited enforcement discretion for those same six peptides. In plain terms, the FDA says it does not intend to take action against licensed compounders who work with them, as long as they meet a strict list of conditions.
- What it is not: This is not FDA approval, and it does not formally add any peptide to the FDA’s list of approved compounding ingredients. That still requires a separate rulemaking process.
- For research use only (RUO) suppliers: Nothing about RUO status has changed. The policy applies to licensed pharmacies, federal facilities, and physicians, not to research chemical suppliers.
Step 1: The July advisory committee vote
The PCAC is an outside panel that advises the FDA on which bulk ingredients compounding pharmacies should be allowed to use. Its votes are recommendations only. They are not binding on the agency.
Over two days in late July, the committee reviewed seven nominated peptides. According to ABC News, the panel narrowly voted to recommend six of them for the 503A bulks list:
- BPC-157
- TB-500
- KPV
- MOTS-c
- Epitalon
- Semax
The seventh, emideltide, was rejected. Reporting on the meeting noted that the evidence presented for it was especially thin, and that the studies cited did not match the way it had been proposed for use.
The most notable detail from the meeting: FDA staff scientists opposed adding every one of the peptides. Their stated concerns included a lack of solid clinical trial data, inconsistent batch-to-batch manufacturing, and the risk of unwanted immune reactions. TIME described the outcome as the committee voting in favor of the peptides despite the agency’s opposition.
That split between the advisory panel and the FDA’s own reviewers is a big part of why what happened next matters.
Step 2: The October 28 HHS policy
Normally, after an advisory vote, the FDA would review the record and then propose a formal rule, open it for public comment, and finalize it. That process can take many months or even years.
Instead, on October 28, HHS issued a policy titled “HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” It covers the same six peptides the committee recommended. Drug Topics summarized HHS’s stated purpose as expanding access “while FDA reviews these substances.”
What “enforcement discretion” means
Enforcement discretion is a regulatory tool where an agency says it will not pursue enforcement in a specific situation, even though the activity has not been formally approved. It is a policy decision, not a change in the law, and it can be withdrawn.
Here, the six peptides still are not on the 503A bulks list, still do not have USP monographs, and still are not components of any FDA-approved drug. Those are normally the three ways an ingredient becomes eligible for 503A compounding. The policy simply says the FDA will not act against qualifying compounders while the formal review continues.
The conditions attached
According to a legal analysis published in the National Law Review, compounders must meet all of the following for the policy to apply:
- The peptide must be one of the six listed in the policy, matching the specific identity and limited uses HHS defined for each.
- The bulk ingredient must come from an FDA-registered facility and include a valid Certificate of Analysis.
- The original manufacturer must be FDA-registered and compliant with Current Good Manufacturing Practice (CGMP).
- Serious adverse events must be reported to the FDA’s MedWatch program.
- Products must contain a single active ingredient. No blends.
- Labels must state: “This is a compounded drug product. Not for resale.”
- The product must comply with all other applicable provisions of federal drug law.
HHS also said it may revisit the policy if safety signals or product quality problems appear. No end date was given.
Who it covers, and who it does not
The policy applies to state-licensed pharmacies, federal facilities, and licensed physicians compounding under section 503A. Larger 503B outsourcing facilities are not covered. Peptides that were not part of the July review, including CJC-1295, Ipamorelin, and AOD-9604, are not covered either. Neither is emideltide.
Step 3: The pushback
Not everyone agrees with the decision. In October, the Partnership for Safe Medicines, a patient safety advocacy group, filed a citizen petition asking the FDA not to allow compounding of the peptides reviewed in July, calling them “untested and poorly defined.”
The policy itself also opened a short public comment window, roughly two weeks after its publication in the Federal Register. The comments, along with the July meeting record, are expected to inform the FDA’s eventual rulemaking.
What happens next
The enforcement discretion policy is a temporary bridge, not a final answer. The FDA still has to decide, through formal notice-and-comment rulemaking, whether any of the six peptides belong on the 503A bulks list permanently. NCPA, which represents independent pharmacies, noted that no timeframe has been given. Expect continued uncertainty heading into 2027.
Things worth watching:
- Whether the FDA publishes proposed rules for any of the six peptides, and how closely they track the committee’s recommendations
- Whether any safety or quality problems lead HHS to narrow or withdraw the policy
- How the FDA responds to the citizen petition
- Whether additional peptides are nominated for future advisory committee review
What this means for the research peptide market
It is easy to read headlines like “FDA allows peptides” and assume the rules changed across the board. They did not.
Research use only status is unchanged. The October policy concerns compounded drug products made by licensed professionals. It does not create any pathway for research chemicals to be used outside a laboratory, and it does not change how RUO compounds may be sold or labeled. If you want a refresher on what that designation actually means, see our post on what “Research Use Only” really means.
HHS was direct about the RUO market. Part of the stated reasoning behind the policy was to offer a supervised alternative to research-use-only peptides entering the market from overseas without adequate safeguards. We think that concern is fair. It is the same problem we have written about in why peptide research is receiving increased regulatory scrutiny, and it is why we publish full testing data for every batch.
Documentation is becoming the baseline. Look at the conditions HHS attached: registered facilities, valid Certificates of Analysis, traceable manufacturers. Regulators are signaling that documented identity, purity, and sourcing are the minimum expectation. That standard is worth applying to any research supplier. Our guide on how to read a peptide Certificate of Analysis covers what to look for, and why endotoxin testing matters explains a test many vendors skip.
Where Apex Peptide Supply stands
Our position has not changed. Apex Peptide Supply sells peptides strictly for laboratory research use. We are not a compounding pharmacy, and this policy does not apply to us or to our products.
What we can control is transparency. Every batch we sell is tested for identity by mass spectrometry, for purity by HPLC, and for endotoxin, with a second independent lab used as a cross-check. Results for current and past batches are posted on our Certificate of Analysis page, and our full process is outlined on our Research Standards page.
We will keep following the rulemaking and update this post as the FDA acts. For background on two of the compounds involved, see our research overviews of BPC-157 and TB-500.
Frequently asked questions
Did the FDA approve BPC-157 or TB-500?
No. Enforcement discretion is not FDA approval. None of the six peptides has been approved as a drug, and none has been formally added to the 503A bulks list. The FDA has said only that it does not intend to take action against qualifying licensed compounders while it reviews these substances.
Which peptides are covered by the October 2026 HHS policy?
BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax. Emideltide (DSIP), which the advisory committee voted against, is not covered.
Is the policy permanent?
No. It is an interim policy with no stated end date, and HHS said it may revisit it if safety or quality concerns arise. Permanent status would require formal FDA rulemaking.
Does this change anything for research use only peptides?
No. The policy applies only to state-licensed pharmacies, federal facilities, and licensed physicians compounding under section 503A. Research-use-only compounds remain restricted to laboratory research and are not intended for human use.
Why did FDA scientists oppose the peptides?
According to reporting on the July meeting, FDA reviewers cited limited clinical trial data, inconsistent batch-to-batch manufacturing, and the potential for immune reactions.
Research-use-only notice
All products supplied by Apex Peptide Supply are sold strictly for laboratory research use only (RUO). They are not drugs, foods, cosmetics, or medical devices, and are not intended for human or veterinary use, consumption, diagnosis, treatment, or the prevention of any disease. This article summarizes publicly reported regulatory developments for informational purposes only. It is not legal or medical advice and does not describe or imply any biological, clinical, or therapeutic effect of any compound. All work with research compounds must be performed by qualified individuals in an appropriate setting, in accordance with all applicable laws and institutional requirements.